Additional Information Development Pipeline as at 31 December 2015 Includes AstraZeneca sponsored or directed studies only.
Phase III Pivotal Phase II Registration NMEs and significant additional indications Regulatory submission dates shown for assets in Phase III and beyond.
As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.
Date Estimated Regulatory Submission Submission Acceptance Commenced Compound Mechanism Area Under Investigation Phase US EU Japan China Respiratory, Inflammation and Autoimmunity # anifrolumab TULIP IFN-alphaR MAb systemic lupus erythematosus Q3 2015 2019 2019 2019 Fast Track # benralizumab CALIMA IL-5R MAb severe asthma Q4 2013 H2 2016 H2 2016 N A N A SIROCCO ZONDA BISE BORA GREGALE # benralizumab IL-5R MAb COPD Q3 2014 2018 2018 N A N A TERRANOVA GALATHEA # 1 brodalumab IL-17R MAb psoriasis Q3 2012 Accepted Accepted N A N A AMAGINE-1,2, 3 2 Zurampic lesinurad selective uric acid chronic treatment of Q4 2011 Approved Accepted CLEAR 1,2 CRYSTAL reabsorption inhibitor hyperuricemia in patients URAT-1 with gout PT003 GFF PINNACLE LABA LAMA COPD Q2 2013 Accepted H2 2016 2017 2017 PT010 LABA LAMA ICS COPD Q3 2015 2018 2018 2017 2019 tralokinumab STRATOS 1,2 IL-13 MAb severe asthma Q3 2014 2018 2018 2018 TROPOS MESOS Cardiovascular and Metabolic diseases 3 Brilinta Brilique P2Y12 receptor antagonist arterial thrombosis Launched Launched Accepted Launched # Epanova omega-3 carboxylic acids severe hypertriglyceridemia Approved 2018 2019 4 Farxiga Forxiga SGLT2 inhibitor Type 2 diabetes Launched Launched Launched Accepted # 5 roxadustat OLYMPUS hypoxia-inducible factor prolyl anaemia in CKD ESRD Q3 2014 2018 N A N A H2 2016 ROCKIES hydroxylase inhibitor ZS-9 sodium zirconium potassium binder hyperkalaemia Accepted Accepted cyclosilicate Oncology #6 acalabrutinib Bruton's tyrosine kinase BTK B-cell blood cancers H2 2016 inhibitor cediranib ICON 6 VEGFR tyrosine kinase inhibitor PSR ovarian cancer Q2 2007 Accepted Orphan Drug # durvalumab PACIFIC PD-L1 MAb stage III NSCLC Q2 2014 2017 2020 2020 # durvalumab HAWK PD-L1 MAb 2nd line SCCHN PD-L1 positive Q1 2015 2017 2019 2019 Fast Track # durvalumab PD-L1 MAb CTLA-4 MAb metastatic pancreatic ductal Q4 2015 2017 2017 2017 tremelimumab ALPS carcinoma # durvalumab tremelimumab PD-L1 MAb CTLA-4 MAb 3rd line NSCLC Q2 2015 2017 2017 2017 ARCTIC # durvalumab tremelimumab PD-L1 MAb CTLA-4 MAb 2nd line SCCHN PD-L1 negative Q2 2015 2017 2019 2019 CONDOR # durvalumab tremelimumab PD-L1 MAb CTLA-4 MAb 1st line bladder Q4 2015 2018 2018 2018 DANUBE # durvalumab tremelimumab PD-L1 MAb CTLA-4 MAb 2nd line SCCHN Q4 2015 2019 2019 2019 EAGLE # durvalumab tremelimumab PD-L1 MAb CTLA-4 MAb 1st line SCCHN Q4 2015 2018 2018 2018 KESTREL # durvalumab tremelimumab PD-L1 MAb CTLA-4 MAb 1st line NSCLC Q3 2015 2017 2017 2017 MYSTIC # durvalumab tremelimumab PD-L1 MAb CTLA-4 MAb 1st line NSCLC Q4 2015 2019 2019 2019 NEPTUNE # moxetumomab pasudotox anti-CD22 recombinant hairy cell leukaemia Q2 2013 2017 2018 PLAIT immunotoxin Orphan Drug # selumetinib ASTRA MEK inhibitor differentiated thyroid cancer Q3 2013 2018 2018 # selumetinib SELECT-1 MEK inhibitor 2nd line KRASm NSCLC Q4 2013 2017 2017 7 Tagrisso AZD9291 AURA, EGFR tyrosine kinase inhibitor 2nd line advanced EGFRm Q2 2014 Launched Approved Accepted 2017 AURA 2 T790M NSCLC Breakthrough Accelerated Priority designation, assessment Review Priority Review, Orphan Drug AstraZeneca Annual Report and Form 20-F Information 2015 205 Additional Information Development Pipeline continued Date Estimated Regulatory Submission Submission Acceptance Commenced Compound Mechanism Area Under Investigation Phase US EU Japan China Tagrisso AZD9291 AURA 3 EGFR tyrosine kinase inhibitor 2nd line advanced EGFRm Q3 2014 2017 2017 2017 T790M NSCLC tremelimumab DETERMINE CTLA-4 MAb mesothelioma Q2 2014 H2 2016 H2 2016 H2 2016 Orphan Drug, Fast Track Infection, Neuroscience and Gastrointestinal # CAZ AVI cephalosporin beta lactamase serious infections, complicated Q1 2012 N A Accepted 2017 inhibitor intra-abdominal infection, complicated urinary tract infection # CAZ AVI cephalosporin beta lactamase hospital-acquired pneumonia Q2 2013 N A Accepted 2017 inhibitor  pneumonia 8 MEDI-550 pandemic influenza virus pandemic influenza prophylaxis N A H1 2016 N A N A vaccine # Zinforo extended spectrum pneumonia skin infections N A Launched N A Submitted cephalosporin with affinity to penicillin-binding proteins 1 6 U S and EU dates correspond to anticipated acceptance US regulatory submission accepted in Q1 2016.
Completion of the agreement with Acerta Pharma Q1 2016.
CHMP Positive Opinion received December 2015.
C HMP Positive Opinion received December 2015.
Approval 3 # Partnered and or in collaboration.
Brilinta in the US: Brilique in rest of world.
4 8 Registrational Phase II III trial.
Farxiga in the US: Forxiga in rest of world.
Regulatory acceptance 5 Rolling NDA submission to be initiated in H2 2016. anticipated H1 2016.
Phases I and II NMEs and significant additional indications Date Commenced Compound Mechanism Area Under Investigation Phase Phase Respiratory, Inflammation and Autoimmunity abediterol AZD0548 LABA asthma COPD II Q4 2007 # anifrolumab IFN-alphaR MAb lupus nephritis II Q4 2015 AZD7594 inhaled SGRM asthma COPD II Q3 2015 AZD7624 inhaled P38 inhibitor COPD II Q4 2014 # AZD9412 inhaled interferon beta asthma COPD II Q3 2015 # mavrilimumab GM-CSFR MAb rheumatoid arthritis II Q1 2010 # 1 MEDI-551 CD19 MAb neuromyelitis optica II Q1 2015 # MEDI2070 IL-23 MAb Crohns disease II Q1 2013 # abrilumab alpha 4 beta 7 MAb Crohns disease ulcerative colitis II Q4 2012 # MEDI9929 TSLP MAb asthma atopic dermatitis II Q2 2014 PT010 LABA LAMA ICS asthma II Q2 2014 RDEA3170 selective uric acid reabsorption inhibitor chronic treatment of hyperuricemia in patients II Q3 2013 URAT-1 with gout tralokinumab IL-13 MAb atopic dermatitis II Q1 2015 # anifrolumab IFN-alphaR MAb systemic lupus erythematosus subcutaneous I Q4 2015 # AZD1419 TLR9 agonist asthma I Q3 2013 AZD7986 DPP1 COPD I Q4 2014 AZD8871 MABA COPD I Q4 2015 AZD8999 MABA COPD I Q4 2013 AZD9567 oral SGRM rheumatoid arthritis I Q4 2015 lesinurad allopurinol selective uric acid reabsorption inhibitor chronic treatment of hyperuricemia in patients I Q4 2015 URAT-1 xanthine oxidase inhibitor with gout MEDI4920 anti-CD40L-Tn3 fusion protein primary Sjgrens syndrome I Q2 2014 # MEDI5872 B7RP1 MAb systemic lupus erythematosus I Q4 2008 MEDI7836 IL-13 MAb-YTE asthma I Q1 2015 Cardiovascular and Metabolic diseases MEDI6012 LCAT ACS II Q4 2015 AZD4076 anti-miR103 107 oligonucleotide non-alcoholic fatty liver disease non-alcoholic I Q4 2015 steatohepatitis NASH MEDI0382 GLP-1 glucagon dual agonist diabetes obesity I Q1 2015 MEDI4166 PCSK9 GLP-1 MAb peptide fusion diabetes cardiovascular I Q4 2015 MEDI8111 Rh-factor II trauma bleeding I Q1 2014 206 AstraZeneca Annual Report and Form 20-F Information 2015 Additional Information Date Commenced Compound Mechanism Area Under Investigation Phase Phase Oncology # AZD1775 WEE-1 inhibitor ovarian cancer II Q4 2012 AZD2014 mTOR serine threonine kinase inhibitor solid tumours II Q1 2013 AZD3759 BLOOM EGFR tyrosine kinase inhibitor brain metastases in advanced II Q4 2015 EGFRm NSCLC Tagrisso AZD9291 BLOOM EGFR tyrosine kinase inhibitor AZD4547 FGFR tyrosine kinase inhibitor solid tumours II Q4 2011 # AZD5069 durvalumab CXCR2 PD-L1 MAb SCCHN II Q3 2015 # # AZD9150 durvalumab STAT3 inhibitor PD-L1 MAb # AZD5363 AKT kinase inhibitor breast cancer II Q1 2014 # durvalumab PD-L1 MAb solid tumours II Q3 2014 # durvalumab tremelimumab PD-L1 MAb CTLA-4 MAb gastric cancer II Q2 2015 # MEDI-551 CD19 MAb diffuse B-cell lymphoma II Q1 2012 # MEDI-573 IGF MAb metastatic breast cancer II Q2 2012 # savolitinib volitinib MET tyrosine kinase inhibitor papillary renal cell carcinoma II Q2 2014 # selumetinib MEK inhibitor 2nd line KRAS wt NSCLC II Q1 2013 AZD0156 ATM serine threonine kinase inhibitor solid tumours I Q4 2015 AZD2811 Aurora B kinase inhibitor solid tumours I Q4 2015 # AZD5312 androgen receptor inhibitor solid tumours I Q2 2014 AZD6738 ATR serine threonine kinase inhibitor solid tumours I Q4 2013 AZD8186 PI3 kinase beta inhibitor solid tumours I Q2 2013 AZD8835 PI3 kinase alpha inhibitor solid tumours I Q4 2014 # AZD9150 STAT3 inhibitor haematological malignancies I Q1 2012 # Tagrisso AZD9291 durvalumab or EGFR tyrosine kinase inhibitor PD-L1 MAb or advanced EGFRm NSCLC I Q3 2014 # # selumetinib or savolitinib TATTON MEK inhibitor or MET tyrosine kinase inhibitor AZD9496 selective oestrogen receptor downregulator ER breast cancer I Q4 2014 SERD # durvalumab PD-L1 MAb solid tumours I Q3 2014 # durvalumab MEDI0680 PD-L1 MAb PD-1 MAb solid tumours I Q2 2014 # # durvalumab MEDI6383 OX40 agonist PD-L1 MAb solid tumours I Q2 2015 # 2 durvalumab dabrafenib trametinib PD-L1 MAb BRAF inhibitor MEK inhibitor melanoma I Q1 2014 # durvalumab tremelimumab PD-L1 MAb CTLA-4 MAb solid tumours I Q4 2013 # Iressa durvalumab PD-L1 MAb EGFR tyrosine kinase inhibitor NSCLC I Q2 2014 # MEDI0562 humanised OX40 agonist solid tumours I Q1 2015 # MEDI-551 rituximab CD19 MAb CD20 MAb haematological malignancies I Q2 2014 # MEDI-565 CEA BiTE MAb solid tumours I Q1 2011 # MEDI0639 DLL-4 MAb solid tumours I Q2 2012 MEDI0680 PD-1 MAb solid tumours I Q4 2013 MEDI1873 GITR agonist fusion protein solid tumours I Q4 2015 # MEDI3617 ANG-2 MAb solid tumours I Q4 2010 MEDI4276 HER2 bispecific ADC MAb solid tumours I Q4 2015 # MEDI6383 OX40 agonist solid tumours I Q3 2014 # MEDI9197 TLR 7 8 agonist solid tumours I Q4 2015 MEDI9447 CD73 MAb solid tumours I Q3 2015 Infection, Neuroscience and Gastrointestinal AZD3241 myeloperoxidase inhibitor multiple system atrophy II Q2 2015 Orphan Drug # AZD3293 beta-secretase inhibitor Alzheimers disease II Q4 2014 # CXL beta lactamase inhibitor cephalosporin  S. aureus II Q4 2010 MEDI7510 RSV sF GLA-SE prevention of RSV disease in older adults II Q3 2015 MEDI8852 influenza A MAb influenza A treatment II Q4 2015 # MEDI8897 RSV MAb-YTE passive RSV prophylaxis II Q1 2015 FDA Fast Track MEDI4893 MAb binding to S. aureus toxin hospital-acquired pneumonia serious S. aureus II Q4 2014 infection FDA Fast Track # ATM AVI monobactam beta lactamase inhibitor targeted serious bacterial infections I Q4 2012 AZD8108 NMDA antagonist suicidal ideation I Q4 2014 MEDI1814 amyloid beta MAb Alzheimers disease I Q2 2014 MEDI3902 anti-Psl PcrV prevention of nosocomial pseudomonas I Q3 2014 pneumonia FDA Fast Track # Partnered and or in collaboration.
1 Neuromyelitis optica: Now lead indication.
Multiple sclerosis trial completed in 2015.
2 MedImmune-sponsored trial in collaboration with Novartis AG.
AstraZeneca Annual Report and Form 20-F Information 2015 207 Additional Information Development Pipeline continued Significant Life-Cycle Management Date Estimated Regulatory Submission Acceptance Commenced Compound Mechanism Area Under Investigation Phase US EU Japan China Respiratory, Inflammation and Autoimmunity # Duaklir Genuair LAMA LABA COPD 2018 Launched 2018 2018 Symbicort SYGMA ICS LABA as-needed use in mild asthma Q4 2014 N A 2018 2019 Symbicort ICS LABA breath actuated inhaler asthma COPD 2018 Cardiovascular and Metabolic diseases 1 Brilinta Brilique EUCLID P2Y12 receptor antagonist outcomes trial in patients with peripheral Q4 2012 2017 2017 2017 2018 artery disease 1 Brilinta Brilique HESTIA P2Y12 receptor antagonist prevention of vaso-occlusive crises in Q4 2014 2020 2020 paediatric patients with sickle cell disease 1 2 Brilinta Brilique P2Y12 receptor antagonist outcomes trial in patients with prior Q4 2010 Launched Accepted Accepted H2 2016 PEGASUS-TIMI 54 myocardial infarction Priority Review 1 Brilinta Brilique SOCRATES P2Y12 receptor antagonist outcomes trial in patients with stroke Q1 2014 H1 2016 H1 2016 H2 2016 2017 or TIA 1 Brilinta Brilique THEMIS P2Y12 receptor antagonist outcomes trial in patients with Type 2 Q1 2014 2018 2018 2018 2019 diabetes and CAD, but without a previous history of MI or stroke Bydureon EXSCEL GLP-1 receptor agonist Type 2 diabetes outcomes trial Q2 2010 2018 2018 2018 Bydureon weekly suspension GLP-1 receptor agonist Type 2 diabetes Q1 2013 2017 2017 Epanova STRENGTH omega-3 carboxylic acids outcomes trial in statin-treated Q4 2014 2020 2020 2020 2020 patients at high CV risk, with persistent hypertriglyceridemia plus low HDL-cholesterol 3 Epanova Farxiga Forxiga omega-3 carboxylic acids non-alcoholic fatty liver disease Q1 2015 SGLT2 inhibitor non-alcoholic steatohepatitis NASH 3 Farxiga Forxiga SGLT2 inhibitor Type 2 diabetes outcomes trial Q2 2013 2020 2020 DECLARE-TIMI 58 3 Farxiga Forxiga SGLT2 inhibitor Type 1 diabetes Q4 2014 2018 2017 2018 4 Kombiglyze XR Komboglyze DPP-4 inhibitor metformin Type 2 diabetes Launched Launched Submitted FDC 5 Onglyza SAVOR-TIMI 53 DPP-4 inhibitor Type 2 diabetes outcomes trial Q2 2010 Accepted Launched H2 2016 6 saxagliptin dapagliflozin FDC DPP-4 inhibitor SGLT2 Type 2 diabetes Q2 2012 Accepted Accepted inhibitor FDC 7 Xigduo XR Xigduo SGLT2 inhibitor metformin Type 2 diabetes Launched Launched FDC Oncology Faslodex FALCON oestrogen receptor antagonist 1st line hormone receptor five Q4 2012 H2 2016 H2 2016 H2 2016 2020 advanced breast cancer Lynparza olaparib SOLO-1 PARP inhibitor 1st line BRCAm ovarian cancer Q3 2013 2017 2017 2017 Lynparza olaparib SOLO-2 PARP inhibitor 2nd line or greater BRCAm PSR ovarian Q3 2013 H2 2016 2017 2017 cancer, maintenance monotherapy Lynparza olaparib SOLO-3 PARP inhibitor gBRCA PSR ovarian cancer Q1 2015 2018 Lynparza olaparib GOLD PARP inhibitor 2nd line gastric cancer Q3 2013 2017 Lynparza olaparib OlympiA PARP inhibitor gBRCA adjuvant breast cancer Q2 2014 2020 2020 2020 Lynparza olaparib OlympiAD PARP inhibitor gBRCA metastatic breast cancer Q2 2014 H2 2016 2017 2017 Lynparza olaparib POLO PARP inhibitor pancreatic cancer Q1 2015 2018 2018 2018 Lynparza olaparib PARP inhibitor prostate cancer Q3 2014 Breakthrough Therapy 8 designation Tagrisso AZD9291 ADAURA EGFR tyrosine kinase inhibitor adjuvant EGFRm NSCLC Q4 2015 2022 2022 Tagrisso AZD9291 FLAURA EGFR tyrosine kinase inhibitor 1st line advanced EGFRm NSCLC Q1 2015 2017 2017 2017 2020 Tagrisso AZD9291 EGFR tyrosine kinase inhibitor 2nd line advanced EGFRm T790M Q3 2015 # 9 durvalumab CAURAL PD-L1 MAb NSCLC 208 AstraZeneca Annual Report and Form 20-F Information 2015 Additional Information Date Estimated Regulatory Submission Acceptance Commenced Compound Mechanism Area Under Investigation Phase US EU Japan China Infection, Neuroscience and Gastrointestinal # Diprivan sedative and anaesthetic conscious sedation N A Launched Accepted Launched # 10 linaclotide GC-C receptor peptide irritable bowel syndrome with N A N A N A Accepted agonist constipation IBS-C Nexium proton pump inhibitor stress ulcer prophylaxis H2 2016 Nexium proton pump inhibitor paediatrics Launched Launched H2 2016 Accepted 4 8 US and EU dates correspond to anticipated acceptance Kombiglyze XR in the US: Komboglyze in the EU.
B reakthrough Therapy designation granted for prostate 5 of the regulatory submission.
T iming of China submission dependent on US cancer patients with BRCA1 2 or ATM gene mutated # Partnered and or in collaboration.
mCRPC who have received previous taxane-based 1 6 Brilinta in the US: Brilique in rest of world.
CRL received October 2015. chemotherapy and one newer hormonal agent abiraterone 2 7 CHMP Positive Opinion received December 2015.
Xigduo XR in the US: Xigduo in the EU.
3 9 Farxiga in the US: Forxiga in rest of world.
Terminations NME Line Extension Compound Reason for Discontinuation Area Under Investigation # NME AZD2115 Strategic COPD NME AZD5213 Safety efficacy Tourettes syndrome neuropathic pain NME AZD5847 Safety efficacy tuberculosis NME AZD9977 Safety efficacy diabetic kidney disease # NME durvalumab ATLANTIC Strategic 3rd line NSCLC PD-L1 positive # # NME durvalumab MEDI6469 Strategic solid tumours # NME selumetinib SUMIT Safety efficacy uveal melanoma # 1 NME sifalimumab Strategic systemic lupus erythematosus # NME tenapanor AZD1722 Safety efficacy ESRD-Pi CKD with T2DM # NME MEDI-551 MEDI0680 Safety efficacy diffuse large B-cell lymphoma NME MEDI-559 Safety efficacy passive RSV prophylaxis # NME MEDI6469 Strategic solid tumours # NME MEDI6469 rituximab Strategic solid tumours # NME MEDI6469 tremelimumab Strategic solid tumours # LCM brodalumab Lack of efficacy asthma # LCM durvalumab after Tagrisso AZD9291 or Iressa Strategic NSCLC # or selumetinib docetaxel or tremelimumab # LCM MEDI-551 Safety efficacy chronic lymphocytic leukaemia # LCM moxetumomab pasudotox Safety efficacy paediatric acute lymphoblastic leukaemia LCM Nexium Regulatory refractory reflux oesphagitis JP LCM tralokinumab Safety efficacy idiopathic pulmonary fibrosis # Partnered and or in collaboration.
SLE project stopped but molecule under evaluation for alternative indications.
Completed Projects Divestitures Estimated Regulatory Submission Acceptance Completed Compound Mechanism Area Under Investigation Divested US EU Japan China Myalept leptin analogue lipodystrophy Completed Launched Lynparza olaparib capsule PARP inhibitor BRCAm PSR ovarian cancer Completed Launched Launched AZD0914 GyrAR serious bacterial infections Phase III Divested in Phase II #1 Movantik Moventig oral peripherally-acting opioid-induced constipation Completed Launched Launched mu-opioid receptor antagonist Bydureon Dual Chamber Pen GLP-1 receptor agonist Type 2 diabetes Completed Launched Launched Launched 2 brodalumab AMVISION-1,2 IL-17R MAb psoriatic arthritis Partnered 3 4 Caprelsa VEGFR EGFR tyrosine kinase medullary thyroid cancer Divested Launched Launched Approved Accepted inhibitor with RET kinase activity 3 Caprelsa VEGFR EGFR tyrosine kinase differentiated thyroid cancer Divested inhibitor with RET kinase activity 5 Entocort glucocorticoid steroid Crohns disease ulcerative colitis Completed Launched Launched Q4 2015 N A Divested 6 Iressa EGFR tyrosine kinase inhibitor EGFRm NSCLC Completed Launched Launched Launched Launched 7 AZD4901 NK3 receptor antagonist polycystic ovarian syndrome Divested in Phase II 6 U S and EU dates correspond to anticipated acceptance Divested to Genzyme deal completed October 2015.
Approved in Japan in September 2015.
D ivested to Millendo Therapeutics, Inc. Agreement # 5 Partnered and or in collaboration.
G lobal rights, outside the US, divested to Tillotts Pharma announced January 2016.
Movantik in the US: Moventig in EU.
AstraZeneca continues to support the A straZeneca has granted Valeant an exclusive licence Japanese regulatory submission.
to develop and commercialise brodalumab.
AstraZeneca Annual Report and Form 20-F Information 2015 209
